Tessera Therapeutics

Tessera Therapeutics is a company.

Active

Updated: Dec 10, 2025 ·

Recent News & Mentions

Apr 1, 2022FundingTessera Therapeutics - Series C

Financial History

Tessera Therapeutics has raised $300.0M across 1 funding round. Most recently, it raised $300.0M Series C in April 2022.

Total Raised

$300.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Apr 1, 2022	$300.0M Series C		Catalio Capital, Flagship Ventures, Petri

Financial History

Tessera Therapeutics has raised $300.0M across 1 funding round.

Total Raised

$300.0M

Valuation

N/A

Leadership Team

Key people at Tessera Therapeutics.

Jacob Rubens

Co-Founder

Leadership Team

Key people at Tessera Therapeutics.

Jacob Rubens

Co-Founder

Deep Dive

Tessera Therapeutics is an early‑stage biotechnology company that is pioneering a new category of genome engineering called Gene Writing—a platform intended to *write* therapeutic sequences into the genome to produce durable, curative changes for genetic diseases that current gene therapy and editing approaches cannot easily address[1][6]. Tessera was founded within and capitalized by Flagship Pioneering to translate this concept into in‑vivo and ex‑vivo medicines, and it is developing proprietary Gene Writing systems plus targeted lipid nanoparticle (LNP) delivery to reach tissues that are difficult to treat today[6][3].

High‑Level Overview

Mission: Cure disease by writing in the code of life—developing Gene Writing technologies and delivery systems to produce precise, durable therapeutic genomic changes[6][3].
What product it builds: A platform technology (Gene Writing) and associated delivery modalities (proprietary targeted LNPs) intended to enable in‑vivo and ex‑vivo insertion or correction of therapeutic DNA sequences in somatic cells[3][6].
Who it serves: Patients with monogenic and other genetic diseases that are poorly served by existing gene editing or viral gene therapy approaches, plus broader applications across tissue types[1][3].
Problem it solves: Limits of current gene editing/therapy—need for safer, repeatable, and broader ways to introduce small or large genomic changes without reliance on double‑strand breaks, error‑prone repair, or one‑time viral dosing[1][6].
Growth momentum: Founded and incubated by Flagship Pioneering with an R&D team built from leaders at Moderna, Editas, Intellia and others, public program activity (e.g., work toward an in‑vivo sickle cell program supported by philanthropic partners) and participation at industry conventions indicate active preclinical to IND‑enabling progress[6][7][5].

Origin Story

Tessera emerged from Flagship Pioneering’s internal research programs where scientists asked whether there was a better biological way to alter genomes than cutting DNA; that inquiry led to the conception of Gene Writing and the founding of Tessera to commercialize it[1][6]. Key early figures include Flagship partners and founders involved in the effort (e.g., Geoffrey von Maltzahn and other Flagship scientists) and a board/leadership with genetics and RNA therapeutics expertise such as Melissa Moore and John Mendlein[6][1]. The company’s early narrative ties to foundational science from groups studying mobile genetic elements and retroelement biology and builds on historical gene therapy advances while specifically seeking to overcome their limitations[1][6].

Core Differentiators

Platform distinction: *Gene Writing* aims to *write* therapeutic messages (small or large) into genomes rather than primarily relying on nuclease‑driven double‑strand breaks or viral gene addition alone[6][1].
Delivery integration: Development of proprietary targeted LNP delivery systems to enable in‑vivo administration to relevant tissues and to avoid limitations of viral vectors such as dosing constraints[3][7].
Founding and talent pedigree: Founded and funded by Flagship Pioneering with leadership and team members from leading genetic medicine and RNA therapeutics firms (Moderna, Editas, Intellia, Beam, etc.), giving access to deep domain expertise and Flagship’s venture‑creation resources[6][4].
Ambition for scale and accessibility: Programs (e.g., sickle cell disease) emphasize one‑time, scalable in‑vivo approaches intended to be safer and more deployable globally than complex ex‑vivo stem‑cell therapies[7].
Data and engineering practices: Investment in modern data infrastructure and automation (e.g., Quilt/Nextflow on AWS) to manage petabyte‑scale datasets and accelerate iterative discovery[8].

Role in the Broader Tech Landscape

Trend alignment: Tessera rides multiple converging trends—advances in RNA biology, LNP delivery (spurred by mRNA vaccine technologies), and renewed focus on curative genetic medicines—positioning Gene Writing as a potential next phase beyond CRISPR‑based editing and classical gene therapy[6][3].
Timing: Improvements in nonviral delivery, RNA design, and computational biology create a more favorable environment for in‑vivo writing approaches that previously faced delivery and precision barriers[3][8].
Market forces: There is strong scientific, clinical, and philanthropic interest in scalable cures for high‑burden monogenic diseases (e.g., sickle cell disease), and funders are prioritizing modalities that can be delivered globally without complex ex‑vivo manufacturing[7].
Ecosystem influence: If successful, Gene Writing could expand the treatable disease set, reduce dependence on viral‑vector manufacturing, and shift investment and development toward programmable RNA‑based therapeutic platforms[1][6].

Quick Take & Future Outlook

Tessera is positioned as a high‑upside platform company: its prospects depend on demonstrating precise, efficient, and safe in‑vivo writing in relevant tissues and advancing programs to the clinic—milestones that would validate Gene Writing as a new category in genetic medicine[6][3]. Near‑term signals to watch include preclinical-to‑IND data readouts, delivery safety and repeatability profiles, and strategic partnerships or funding that enable global access (for example, philanthropic support mentioned for an SCD program)[7][6]. Over the next several years, broader trends in LNP delivery, regulatory comfort with novel genome‑modifying modalities, and successful clinical outcomes will shape whether Tessera’s approach becomes a mainstream therapeutic route or remains a niche/supplemental technology to existing gene editing and gene therapy methods[3][6].

Key sources: company pages and Flagship Pioneering press materials on Tessera’s Gene Writing concept and focus areas, public reporting on program activity (sickle cell) and technical emphasis on LNP delivery, and technology case studies describing their computational infrastructure[6][3][7][8].

Sources

Frequently Asked Questions

Who founded Tessera Therapeutics?

Tessera Therapeutics was founded by Jacob Rubens (Co-Founder).

How much funding has Tessera Therapeutics raised?

Tessera Therapeutics has raised $300.0M in total across 1 funding round.

Who are Tessera Therapeutics's investors?

Tessera Therapeutics's investors include Catalio Capital, Flagship Ventures, Petri.